Bivalirudin

Drug Profile

Bivalirudin

Alternative Names: Angiomax; Angiox; BG 8967; Hirulog-1

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer The Medicines Company
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 22 Nov 2016 Efficacy data from the phase III BRAVO-2/3 trial in Thrombosis prevention (in patients undergoing transaortic valve replacement) presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2016)
  • 12 Jul 2016 The U.S. Court of Appeals for the Federal Circuit Court unanimously affirms District Circuit decision stating that The Medicines Company's Orange Book patents were not invalid under the on sale baron
  • 01 Sep 2015 Efficacy and adverse events data from the MATRIX phase III trial in Acute coronary syndromes released by the Medicines company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top